GlassScriptPhysician profile
Jena L Schellhammer
NPI 1194950535
$1,887.23
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,086 · 2023: $709 · 2024: $92.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.66 | 2022-2024 | |
| Glaxosmithkline, LLC. | $290.91 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $267.75 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $132.27 | 2022 | |
| Pfizer INC. | $89.72 | 2022-2023 | |
| Tactile Systems Technology INC | $88.03 | 2022-2023 | Entre Plus, Flexitouch Plus |
| Amgen INC. | $77.54 | 2022-2023 | Otezla, Repatha |
| Novo Nordisk INC | $69.50 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $69.11 | 2022-2024 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.98 | 2022 | |
| Merck Sharp & Dohme LLC | $57.47 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
| Gilead Sciences, INC. | $56.96 | 2023 | Epclusa |
| Abbott Laboratories | $47.52 | 2022 | |
| Xeris Pharmaceuticals, INC. | $29.52 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.41 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $15.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jena Schellhammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.